Literature DB >> 7824860

Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients.

S Fiorucci1, E Distrutti, G Bassotti, R Gerli, S Chiucchiù, C Betti, L Santucci, A Morelli.   

Abstract

BACKGROUND: Gastrointestinal involvement is frequent in patients with scleroderma. Erythromycin, a macrolide antibiotic, has been shown to accelerate gastric emptying in normal subjects and diabetic patients. The present study investigated the effects of acute erythromycin administration on gastric and gallbladder motility in patients with scleroderma and gastrointestinal involvement.
METHODS: Twelve scleroderma patients and 14 healthy subjects were investigated. Each subject was investigated on 4 different days. Gastric and gallbladder emptying and gastric motility were determined by sonography and manometry, and the effect of 2 mg/kg/h erythromycin in fasted patients or after semisolid meal evaluated.
RESULTS: The half-time of gastric emptying in response to semisolid meal was 121.3 +/- 14.0 min (SE) in scleroderma patients and 45.7 +/- 10.4 min in healthy subjects (P < 0.01). The peak of gallbladder emptying occurred later in scleroderma patients (95.0 +/- 5.0 min) than in healthy subjects (45.0 +/- 8.0 min) (P < 0.01). Erythromycin stimulated gastric and gallbladder motility in fasted subjects, as shown by manometry and sonography, and accelerated gastric and gallbladder emptying when administered immediately before the meal (P < 0.01).
CONCLUSIONS: Erythromycin accelerates gastric and gallbladder emptying in scleroderma patients and might be helpful in the treatment of gastrointestinal motor abnormalities in these patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7824860     DOI: 10.3109/00365529409092515

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  Chronic Intestinal Pseudo-obstruction.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

2.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

Review 3.  Childhood gastroparesis is a unique entity in need of further investigation.

Authors:  Liz Febo-Rodriguez; Bruno P Chumpitazi; Robert J Shulman
Journal:  Neurogastroenterol Motil       Date:  2019-08-13       Impact factor: 3.598

Review 4.  [Systemic sclerosis : What is currently available for treatment?]

Authors:  M O Becker
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

5.  Effect of erythromycin on gastric emptying in healthy individuals assessed by radio-opaque markers and plasma acetaminophen levels.

Authors:  H J Park; J K Jung; K S Song; S I Lee; Z Itoh; I S Park
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

6.  Erythromycin dose of 70 mg accelerates gastric emptying as effectively as 200 mg in the critically ill.

Authors:  Marc A Ritz; Marianne J Chapman; Robert J Fraser; Mark E Finnis; Ross N Butler; Patricia Cmielewski; Geoffrey P Davidson; Deborah Rea
Journal:  Intensive Care Med       Date:  2005-06-07       Impact factor: 17.440

7.  Gallbladder motility in systemic sclerosis.

Authors:  G Lock; M Zeuner; M Kammerl; B Lang; J Schölmerich; A Holstege
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 8.  Gastrointestinal manifestations of systemic sclerosis.

Authors:  Robyn Domsic; Kenneth Fasanella; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 9.  A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-03-04       Impact factor: 4.991

Review 10.  Gastrointestinal Involvement in Systemic Sclerosis: An Update.

Authors:  John B Miller; Nisarg Gandhi; John Clarke; Zsuzsanna McMahan
Journal:  J Clin Rheumatol       Date:  2018-09       Impact factor: 3.517

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.